カテゴリー： 世界, 医療/バイオ, Market Monitor Global

13価肺炎球菌結合型ワクチンのグローバル市場展望 2023年-2029年：バイアル、充填済み

【英語タイトル】13-Valent Pneumococcal Conjugate Vaccine Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが出版した調査資料（MMG23DC14206）・商品コード：MMG23DC14206
・発行会社（調査会社）：Market Monitor Global
・発行日：2023年12月（※2025年版があります。お問い合わせください。）
・ページ数：70
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
・産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥468,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥608,400見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥702,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界の13価肺炎球菌結合型ワクチン市場規模と予測を収録しています。・世界の13価肺炎球菌結合型ワクチン市場：売上、2018年-2023年、2024年-2029年
・世界の13価肺炎球菌結合型ワクチン市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の13価肺炎球菌結合型ワクチン市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「バイアル」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

13価肺炎球菌結合型ワクチンのグローバル主要企業は、Pfizer、 Kangtai、 Walvax Biotechnologyなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、13価肺炎球菌結合型ワクチンのメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の13価肺炎球菌結合型ワクチン市場：タイプ別、2018年-2023年、2024年-2029年
世界の13価肺炎球菌結合型ワクチン市場：タイプ別市場シェア、2022年
・バイアル、充填済み

世界の13価肺炎球菌結合型ワクチン市場：用途別、2018年-2023年、2024年-2029年
世界の13価肺炎球菌結合型ワクチン市場：用途別市場シェア、2022年
・病院、診療所、CDC

世界の13価肺炎球菌結合型ワクチン市場：地域・国別、2018年-2023年、2024年-2029年
世界の13価肺炎球菌結合型ワクチン市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における13価肺炎球菌結合型ワクチンのグローバル売上、2018年-2023年
・主要企業における13価肺炎球菌結合型ワクチンのグローバル売上シェア、2022年
・主要企業における13価肺炎球菌結合型ワクチンのグローバル販売量、2018年-2023年
・主要企業における13価肺炎球菌結合型ワクチンのグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Pfizer、 Kangtai、 Walvax Biotechnology

*************************************************************

・調査・分析レポートの概要
13価肺炎球菌結合型ワクチン市場の定義
市場セグメント
世界の13価肺炎球菌結合型ワクチン市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の13価肺炎球菌結合型ワクチン市場規模
世界の13価肺炎球菌結合型ワクチン市場規模：2022年 VS 2029年
世界の13価肺炎球菌結合型ワクチン市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの13価肺炎球菌結合型ワクチンの売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の13価肺炎球菌結合型ワクチン製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：バイアル、充填済み
13価肺炎球菌結合型ワクチンのタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、診療所、CDC
13価肺炎球菌結合型ワクチンの用途別グローバル売上・予測

・地域別市場分析
地域別13価肺炎球菌結合型ワクチン市場規模 2022年と2029年
地域別13価肺炎球菌結合型ワクチン売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Pfizer、 Kangtai、 Walvax Biotechnology
...

This research report provides a comprehensive analysis of the 13-Valent Pneumococcal Conjugate Vaccine market, focusing on the current trends, market dynamics, and future prospects. The report explores the global 13-Valent Pneumococcal Conjugate Vaccine market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of 13-Valent Pneumococcal Conjugate Vaccine, challenges faced by the industry, and potential opportunities for market players.
The global 13-Valent Pneumococcal Conjugate Vaccine market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The 13-Valent Pneumococcal Conjugate Vaccine market presents opportunities for various stakeholders, including Hospital, Clinic. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in 13-Valent Pneumococcal Conjugate Vaccine market. Additionally, the growing consumer demand present avenues for market expansion.
The global 13-Valent Pneumococcal Conjugate Vaccine market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the 13-Valent Pneumococcal Conjugate Vaccine market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the 13-Valent Pneumococcal Conjugate Vaccine market.
Market Overview: The report provides a comprehensive overview of the 13-Valent Pneumococcal Conjugate Vaccine market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Vials, Pre-filled), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the 13-Valent Pneumococcal Conjugate Vaccine market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the 13-Valent Pneumococcal Conjugate Vaccine market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the 13-Valent Pneumococcal Conjugate Vaccine market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the 13-Valent Pneumococcal Conjugate Vaccine market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the 13-Valent Pneumococcal Conjugate Vaccine market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the 13-Valent Pneumococcal Conjugate Vaccine market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for 13-Valent Pneumococcal Conjugate Vaccine, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the 13-Valent Pneumococcal Conjugate Vaccine market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
13-Valent Pneumococcal Conjugate Vaccine market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Vials
Pre-filled
Market segment by Application
Hospital
Clinic
CDC
Global 13-Valent Pneumococcal Conjugate Vaccine Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Pfizer
Kangtai
Walvax Biotechnology
Outline of Major Chapters:
Chapter 1: Introduces the definition of 13-Valent Pneumococcal Conjugate Vaccine, market overview.
Chapter 2: Global 13-Valent Pneumococcal Conjugate Vaccine market size in revenue and volume.
Chapter 3: Detailed analysis of 13-Valent Pneumococcal Conjugate Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of 13-Valent Pneumococcal Conjugate Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global 13-Valent Pneumococcal Conjugate Vaccine capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 13-Valent Pneumococcal Conjugate Vaccine Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global 13-Valent Pneumococcal Conjugate Vaccine Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global 13-Valent Pneumococcal Conjugate Vaccine Overall Market Size
2.1 Global 13-Valent Pneumococcal Conjugate Vaccine Market Size: 2022 VS 2029
2.2 Global 13-Valent Pneumococcal Conjugate Vaccine Revenue, Prospects & Forecasts: 2018-2029
2.3 Global 13-Valent Pneumococcal Conjugate Vaccine Sales: 2018-2029
3 Company Landscape
3.1 Top 13-Valent Pneumococcal Conjugate Vaccine Players in Global Market
3.2 Top Global 13-Valent Pneumococcal Conjugate Vaccine Companies Ranked by Revenue
3.3 Global 13-Valent Pneumococcal Conjugate Vaccine Revenue by Companies
3.4 Global 13-Valent Pneumococcal Conjugate Vaccine Sales by Companies
3.5 Global 13-Valent Pneumococcal Conjugate Vaccine Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 13-Valent Pneumococcal Conjugate Vaccine Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers 13-Valent Pneumococcal Conjugate Vaccine Product Type
3.8 Tier 1, Tier 2 and Tier 3 13-Valent Pneumococcal Conjugate Vaccine Players in Global Market
3.8.1 List of Global Tier 1 13-Valent Pneumococcal Conjugate Vaccine Companies
3.8.2 List of Global Tier 2 and Tier 3 13-Valent Pneumococcal Conjugate Vaccine Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global 13-Valent Pneumococcal Conjugate Vaccine Market Size Markets, 2022 & 2029
4.1.2 Vials
4.1.3 Pre-filled
4.2 By Type – Global 13-Valent Pneumococcal Conjugate Vaccine Revenue & Forecasts
4.2.1 By Type – Global 13-Valent Pneumococcal Conjugate Vaccine Revenue, 2018-2023
4.2.2 By Type – Global 13-Valent Pneumococcal Conjugate Vaccine Revenue, 2024-2029
4.2.3 By Type – Global 13-Valent Pneumococcal Conjugate Vaccine Revenue Market Share, 2018-2029
4.3 By Type – Global 13-Valent Pneumococcal Conjugate Vaccine Sales & Forecasts
4.3.1 By Type – Global 13-Valent Pneumococcal Conjugate Vaccine Sales, 2018-2023
4.3.2 By Type – Global 13-Valent Pneumococcal Conjugate Vaccine Sales, 2024-2029
4.3.3 By Type – Global 13-Valent Pneumococcal Conjugate Vaccine Sales Market Share, 2018-2029
4.4 By Type – Global 13-Valent Pneumococcal Conjugate Vaccine Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global 13-Valent Pneumococcal Conjugate Vaccine Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Clinic
5.1.4 CDC
5.2 By Application – Global 13-Valent Pneumococcal Conjugate Vaccine Revenue & Forecasts
5.2.1 By Application – Global 13-Valent Pneumococcal Conjugate Vaccine Revenue, 2018-2023
5.2.2 By Application – Global 13-Valent Pneumococcal Conjugate Vaccine Revenue, 2024-2029
5.2.3 By Application – Global 13-Valent Pneumococcal Conjugate Vaccine Revenue Market Share, 2018-2029
5.3 By Application – Global 13-Valent Pneumococcal Conjugate Vaccine Sales & Forecasts
5.3.1 By Application – Global 13-Valent Pneumococcal Conjugate Vaccine Sales, 2018-2023
5.3.2 By Application – Global 13-Valent Pneumococcal Conjugate Vaccine Sales, 2024-2029
5.3.3 By Application – Global 13-Valent Pneumococcal Conjugate Vaccine Sales Market Share, 2018-2029
5.4 By Application – Global 13-Valent Pneumococcal Conjugate Vaccine Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global 13-Valent Pneumococcal Conjugate Vaccine Market Size, 2022 & 2029
6.2 By Region – Global 13-Valent Pneumococcal Conjugate Vaccine Revenue & Forecasts
6.2.1 By Region – Global 13-Valent Pneumococcal Conjugate Vaccine Revenue, 2018-2023
6.2.2 By Region – Global 13-Valent Pneumococcal Conjugate Vaccine Revenue, 2024-2029
6.2.3 By Region – Global 13-Valent Pneumococcal Conjugate Vaccine Revenue Market Share, 2018-2029
6.3 By Region – Global 13-Valent Pneumococcal Conjugate Vaccine Sales & Forecasts
6.3.1 By Region – Global 13-Valent Pneumococcal Conjugate Vaccine Sales, 2018-2023
6.3.2 By Region – Global 13-Valent Pneumococcal Conjugate Vaccine Sales, 2024-2029
6.3.3 By Region – Global 13-Valent Pneumococcal Conjugate Vaccine Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America 13-Valent Pneumococcal Conjugate Vaccine Revenue, 2018-2029
6.4.2 By Country – North America 13-Valent Pneumococcal Conjugate Vaccine Sales, 2018-2029
6.4.3 US 13-Valent Pneumococcal Conjugate Vaccine Market Size, 2018-2029
6.4.4 Canada 13-Valent Pneumococcal Conjugate Vaccine Market Size, 2018-2029
6.4.5 Mexico 13-Valent Pneumococcal Conjugate Vaccine Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe 13-Valent Pneumococcal Conjugate Vaccine Revenue, 2018-2029
6.5.2 By Country – Europe 13-Valent Pneumococcal Conjugate Vaccine Sales, 2018-2029
6.5.3 Germany 13-Valent Pneumococcal Conjugate Vaccine Market Size, 2018-2029
6.5.4 France 13-Valent Pneumococcal Conjugate Vaccine Market Size, 2018-2029
6.5.5 U.K. 13-Valent Pneumococcal Conjugate Vaccine Market Size, 2018-2029
6.5.6 Italy 13-Valent Pneumococcal Conjugate Vaccine Market Size, 2018-2029
6.5.7 Russia 13-Valent Pneumococcal Conjugate Vaccine Market Size, 2018-2029
6.5.8 Nordic Countries 13-Valent Pneumococcal Conjugate Vaccine Market Size, 2018-2029
6.5.9 Benelux 13-Valent Pneumococcal Conjugate Vaccine Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia 13-Valent Pneumococcal Conjugate Vaccine Revenue, 2018-2029
6.6.2 By Region – Asia 13-Valent Pneumococcal Conjugate Vaccine Sales, 2018-2029
6.6.3 China 13-Valent Pneumococcal Conjugate Vaccine Market Size, 2018-2029
6.6.4 Japan 13-Valent Pneumococcal Conjugate Vaccine Market Size, 2018-2029
6.6.5 South Korea 13-Valent Pneumococcal Conjugate Vaccine Market Size, 2018-2029
6.6.6 Southeast Asia 13-Valent Pneumococcal Conjugate Vaccine Market Size, 2018-2029
6.6.7 India 13-Valent Pneumococcal Conjugate Vaccine Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America 13-Valent Pneumococcal Conjugate Vaccine Revenue, 2018-2029
6.7.2 By Country – South America 13-Valent Pneumococcal Conjugate Vaccine Sales, 2018-2029
6.7.3 Brazil 13-Valent Pneumococcal Conjugate Vaccine Market Size, 2018-2029
6.7.4 Argentina 13-Valent Pneumococcal Conjugate Vaccine Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales, 2018-2029
6.8.3 Turkey 13-Valent Pneumococcal Conjugate Vaccine Market Size, 2018-2029
6.8.4 Israel 13-Valent Pneumococcal Conjugate Vaccine Market Size, 2018-2029
6.8.5 Saudi Arabia 13-Valent Pneumococcal Conjugate Vaccine Market Size, 2018-2029
6.8.6 UAE 13-Valent Pneumococcal Conjugate Vaccine Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Pfizer
7.1.1 Pfizer Company Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer 13-Valent Pneumococcal Conjugate Vaccine Major Product Offerings
7.1.4 Pfizer 13-Valent Pneumococcal Conjugate Vaccine Sales and Revenue in Global (2018-2023)
7.1.5 Pfizer Key News & Latest Developments
7.2 Kangtai
7.2.1 Kangtai Company Summary
7.2.2 Kangtai Business Overview
7.2.3 Kangtai 13-Valent Pneumococcal Conjugate Vaccine Major Product Offerings
7.2.4 Kangtai 13-Valent Pneumococcal Conjugate Vaccine Sales and Revenue in Global (2018-2023)
7.2.5 Kangtai Key News & Latest Developments
7.3 Walvax Biotechnology
7.3.1 Walvax Biotechnology Company Summary
7.3.2 Walvax Biotechnology Business Overview
7.3.3 Walvax Biotechnology 13-Valent Pneumococcal Conjugate Vaccine Major Product Offerings
7.3.4 Walvax Biotechnology 13-Valent Pneumococcal Conjugate Vaccine Sales and Revenue in Global (2018-2023)
7.3.5 Walvax Biotechnology Key News & Latest Developments
8 Global 13-Valent Pneumococcal Conjugate Vaccine Production Capacity, Analysis
8.1 Global 13-Valent Pneumococcal Conjugate Vaccine Production Capacity, 2018-2029
8.2 13-Valent Pneumococcal Conjugate Vaccine Production Capacity of Key Manufacturers in Global Market
8.3 Global 13-Valent Pneumococcal Conjugate Vaccine Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 13-Valent Pneumococcal Conjugate Vaccine Supply Chain Analysis
10.1 13-Valent Pneumococcal Conjugate Vaccine Industry Value Chain
10.2 13-Valent Pneumococcal Conjugate Vaccine Upstream Market
10.3 13-Valent Pneumococcal Conjugate Vaccine Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 13-Valent Pneumococcal Conjugate Vaccine Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of 13-Valent Pneumococcal Conjugate Vaccine in Global Market
Table 2. Top 13-Valent Pneumococcal Conjugate Vaccine Players in Global Market, Ranking by Revenue (2022)
Table 3. Global 13-Valent Pneumococcal Conjugate Vaccine Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global 13-Valent Pneumococcal Conjugate Vaccine Revenue Share by Companies, 2018-2023
Table 5. Global 13-Valent Pneumococcal Conjugate Vaccine Sales by Companies, (K Units), 2018-2023
Table 6. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers 13-Valent Pneumococcal Conjugate Vaccine Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers 13-Valent Pneumococcal Conjugate Vaccine Product Type
Table 9. List of Global Tier 1 13-Valent Pneumococcal Conjugate Vaccine Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 13-Valent Pneumococcal Conjugate Vaccine Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global 13-Valent Pneumococcal Conjugate Vaccine Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global 13-Valent Pneumococcal Conjugate Vaccine Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global 13-Valent Pneumococcal Conjugate Vaccine Sales (K Units), 2018-2023
Table 15. By Type - Global 13-Valent Pneumococcal Conjugate Vaccine Sales (K Units), 2024-2029
Table 16. By Application – Global 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global 13-Valent Pneumococcal Conjugate Vaccine Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global 13-Valent Pneumococcal Conjugate Vaccine Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global 13-Valent Pneumococcal Conjugate Vaccine Sales (K Units), 2018-2023
Table 20. By Application - Global 13-Valent Pneumococcal Conjugate Vaccine Sales (K Units), 2024-2029
Table 21. By Region – Global 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global 13-Valent Pneumococcal Conjugate Vaccine Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global 13-Valent Pneumococcal Conjugate Vaccine Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global 13-Valent Pneumococcal Conjugate Vaccine Sales (K Units), 2018-2023
Table 25. By Region - Global 13-Valent Pneumococcal Conjugate Vaccine Sales (K Units), 2024-2029
Table 26. By Country - North America 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America 13-Valent Pneumococcal Conjugate Vaccine Sales, (K Units), 2018-2023
Table 29. By Country - North America 13-Valent Pneumococcal Conjugate Vaccine Sales, (K Units), 2024-2029
Table 30. By Country - Europe 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe 13-Valent Pneumococcal Conjugate Vaccine Sales, (K Units), 2018-2023
Table 33. By Country - Europe 13-Valent Pneumococcal Conjugate Vaccine Sales, (K Units), 2024-2029
Table 34. By Region - Asia 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia 13-Valent Pneumococcal Conjugate Vaccine Sales, (K Units), 2018-2023
Table 37. By Region - Asia 13-Valent Pneumococcal Conjugate Vaccine Sales, (K Units), 2024-2029
Table 38. By Country - South America 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America 13-Valent Pneumococcal Conjugate Vaccine Sales, (K Units), 2018-2023
Table 41. By Country - South America 13-Valent Pneumococcal Conjugate Vaccine Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales, (K Units), 2024-2029
Table 46. Pfizer Company Summary
Table 47. Pfizer 13-Valent Pneumococcal Conjugate Vaccine Product Offerings
Table 48. Pfizer 13-Valent Pneumococcal Conjugate Vaccine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. Pfizer Key News & Latest Developments
Table 50. Kangtai Company Summary
Table 51. Kangtai 13-Valent Pneumococcal Conjugate Vaccine Product Offerings
Table 52. Kangtai 13-Valent Pneumococcal Conjugate Vaccine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 53. Kangtai Key News & Latest Developments
Table 54. Walvax Biotechnology Company Summary
Table 55. Walvax Biotechnology 13-Valent Pneumococcal Conjugate Vaccine Product Offerings
Table 56. Walvax Biotechnology 13-Valent Pneumococcal Conjugate Vaccine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 57. Walvax Biotechnology Key News & Latest Developments
Table 58. 13-Valent Pneumococcal Conjugate Vaccine Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 59. Global 13-Valent Pneumococcal Conjugate Vaccine Capacity Market Share of Key Manufacturers, 2021-2023
Table 60. Global 13-Valent Pneumococcal Conjugate Vaccine Production by Region, 2018-2023 (K Units)
Table 61. Global 13-Valent Pneumococcal Conjugate Vaccine Production by Region, 2024-2029 (K Units)
Table 62. 13-Valent Pneumococcal Conjugate Vaccine Market Opportunities & Trends in Global Market
Table 63. 13-Valent Pneumococcal Conjugate Vaccine Market Drivers in Global Market
Table 64. 13-Valent Pneumococcal Conjugate Vaccine Market Restraints in Global Market
Table 65. 13-Valent Pneumococcal Conjugate Vaccine Raw Materials
Table 66. 13-Valent Pneumococcal Conjugate Vaccine Raw Materials Suppliers in Global Market
Table 67. Typical 13-Valent Pneumococcal Conjugate Vaccine Downstream
Table 68. 13-Valent Pneumococcal Conjugate Vaccine Downstream Clients in Global Market
Table 69. 13-Valent Pneumococcal Conjugate Vaccine Distributors and Sales Agents in Global Market
List of Figures
Figure 1. 13-Valent Pneumococcal Conjugate Vaccine Segment by Type in 2022
Figure 2. 13-Valent Pneumococcal Conjugate Vaccine Segment by Application in 2022
Figure 3. Global 13-Valent Pneumococcal Conjugate Vaccine Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global 13-Valent Pneumococcal Conjugate Vaccine Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global 13-Valent Pneumococcal Conjugate Vaccine Revenue, 2018-2029 (US$, Mn)
Figure 7. 13-Valent Pneumococcal Conjugate Vaccine Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by 13-Valent Pneumococcal Conjugate Vaccine Revenue in 2022
Figure 9. By Type - Global 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global 13-Valent Pneumococcal Conjugate Vaccine Revenue Market Share, 2018-2029
Figure 11. By Type - Global 13-Valent Pneumococcal Conjugate Vaccine Sales Market Share, 2018-2029
Figure 12. By Type - Global 13-Valent Pneumococcal Conjugate Vaccine Price (US$/Unit), 2018-2029
Figure 13. By Application - Global 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global 13-Valent Pneumococcal Conjugate Vaccine Revenue Market Share, 2018-2029
Figure 15. By Application - Global 13-Valent Pneumococcal Conjugate Vaccine Sales Market Share, 2018-2029
Figure 16. By Application - Global 13-Valent Pneumococcal Conjugate Vaccine Price (US$/Unit), 2018-2029
Figure 17. By Region - Global 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global 13-Valent Pneumococcal Conjugate Vaccine Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global 13-Valent Pneumococcal Conjugate Vaccine Revenue Market Share, 2018-2029
Figure 20. By Region - Global 13-Valent Pneumococcal Conjugate Vaccine Sales Market Share, 2018-2029
Figure 21. By Country - North America 13-Valent Pneumococcal Conjugate Vaccine Revenue Market Share, 2018-2029
Figure 22. By Country - North America 13-Valent Pneumococcal Conjugate Vaccine Sales Market Share, 2018-2029
Figure 23. US 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2018-2029
Figure 24. Canada 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe 13-Valent Pneumococcal Conjugate Vaccine Revenue Market Share, 2018-2029
Figure 27. By Country - Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Market Share, 2018-2029
Figure 28. Germany 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2018-2029
Figure 29. France 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2018-2029
Figure 31. Italy 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2018-2029
Figure 32. Russia 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia 13-Valent Pneumococcal Conjugate Vaccine Revenue Market Share, 2018-2029
Figure 36. By Region - Asia 13-Valent Pneumococcal Conjugate Vaccine Sales Market Share, 2018-2029
Figure 37. China 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2018-2029
Figure 38. Japan 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2018-2029
Figure 41. India 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America 13-Valent Pneumococcal Conjugate Vaccine Revenue Market Share, 2018-2029
Figure 43. By Country - South America 13-Valent Pneumococcal Conjugate Vaccine Sales Market Share, 2018-2029
Figure 44. Brazil 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Market Share, 2018-2029
Figure 48. Turkey 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2018-2029
Figure 49. Israel 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2018-2029
Figure 51. UAE 13-Valent Pneumococcal Conjugate Vaccine Revenue, (US$, Mn), 2018-2029
Figure 52. Global 13-Valent Pneumococcal Conjugate Vaccine Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production 13-Valent Pneumococcal Conjugate Vaccine by Region, 2022 VS 2029
Figure 54. 13-Valent Pneumococcal Conjugate Vaccine Industry Value Chain
Figure 55. Marketing Channels

※参考情報

13価肺炎球菌結合型ワクチン（13-Valent Pneumococcal Conjugate Vaccine）は、肺炎球菌（Streptococcus pneumoniae）によって引き起こされる重篤な感染症を予防することを目的としたワクチンです。このワクチンは、特定の13種類の肺炎球菌の血清型に対して免疫応答を引き起こすように設計されています。肺炎球菌は、成人や高齢者においては肺炎、中耳炎、髄膜炎、敗血症などの感染症を引き起こす重要な病原体です。特に小児においては、重篤な疾患の原因となることが多く、予防接種は公衆衛生の観点から非常に重要です。

このワクチンの最大の特徴は、結合型ワクチンであることです。結合型ワクチンとは、ポリサッカライド抗原をタンパク質に結合させることで、より強力な免疫応答を促進するものです。この方式により、小児とかいった免疫系が未熟な個体でも十分な免疫が形成されることが期待されます。具体的には、ワクチンに含まれるポリサッカライドは、血清型によって異なりますが、これらの抗原は免疫系のB細胞によって識別され、抗体が生成されます。また、ポリサッカライドが結合されたタンパク質はT細胞依存性の免疫応答を誘導し、記憶細胞の形成にも寄与します。

13価肺炎球菌結合型ワクチンは、以下の13種類の肺炎球菌血清型に対して効果があります：1、3、4、5、6A、6B、7F、9V、14、18C、19A、19F、23F。これらは、肺炎球菌感染症の中で実際に多く見られる型であり、これらを対象にした接種が行われることで、感染症の発生率を大幅に減少させることが期待されています。特に、5歳未満の子供たちは、重篤な合併症を引き起こすリスクが高いため、この年齢層での接種は特に重要です。

ワクチンの用途としては、主に小児の予防接種プログラムに組み込まれています。各国の健康当局によって推奨される接種スケジュールは異なりますが、一般的には生後数ヶ月から接種が開始され、数回にわたって接種されます。また、特定のリスクグループ、例えば免疫不全に陥っている子供や慢性疾患を有する成人に対しても接種が推奨されることがあります。さらに、肺炎球菌感染症にかかる医療負担を軽減するためには、成人における接種も重要視されています。

このワクチンの関連技術には、さまざまな製造プロセスがあります。ワクチンは通常、バイオ技術を用いて製造されます。具体的には、遺伝子組換え技術やバイオリアクターを使用し、大量に抗原を生産し、それを精製する方法が取られています。さらに、ワクチンの安定性や免疫原性を高めるために、様々な添加物や保存剤が使用されます。

また、ワクチンの効果に対しての持続性や免疫学的な特性を調査するための研究も進められています。最近では、ワクチン接種後の抗体レベルの変化や、それがどの程度の期間持続するのか、また新しい肺炎球菌の血清型に対する効果についてのデータ収集が行われています。このような研究から得られた知見は、将来のワクチン開発や改良に役立つと考えられています。

13価肺炎球菌結合型ワクチンの導入により、小児における肺炎球菌感染の発生率は大幅に減少しており、全体的な公衆衛生にも良い影響を与えています。感染症の予防は、個々の健康のみならず、社会全体の健康を守るためにも重要であり、このワクチンはその一助となるものです。ワクチン接種に関する情報は日々更新されており、特に新型コロナウイルスの影響を受けた今、各国の保健機関はワクチンの重要性を再認識しています。

最後に、13価肺炎球菌結合型ワクチンは、今後も更なる研究や改良が期待されている分野です。新たな血清型の出現や、既存ワクチンの効果の低下といった問題に対処するためには、持続的な監視と研究が不可欠です。このようにして、肺炎球菌感染症から人々を守るための新しい戦略を見出す努力が続けられることが望まれます。ワクチン接種の重要性を理解し、適切なタイミングでの接種を行うことで、個人の健康を守るだけでなく、コミュニティ全体の健康を守ることについても意識を高めていくことが求められています。


★調査レポート[13価肺炎球菌結合型ワクチンのグローバル市場展望 2023年-2029年：バイアル、充填済み] (コード：MMG23DC14206)販売に関する免責事項を必ずご確認ください。
★調査レポート[13価肺炎球菌結合型ワクチンのグローバル市場展望 2023年-2029年：バイアル、充填済み]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 長時間作用型ペグインターフェロンα2aのグローバル市場展望 2023年-2029年：バイアル、プレフィルドシリンジ
  • 胚用ガラス化キットの世界市場2023-2029：5ml/バイアル、10ml/バイアル、その他
  • インフルエンザ用パンデミックワクチンのグローバル市場展望 2023年-2029年：3価インフルエンザワクチン、4価インフルエンザワクチン

    • ◆H&Iグローバルリサーチのお客様（例）◆